Niraparib for maintenance treatment of platinum-sensitive ovarian cancer after second response to chemotherapy (CDF review of TA528)

£328.1K GBP

Funder	National Institute for Health Research
Recipient Organization	Bmj Publishing Group Limited
Country	United Kingdom
Start Date	May 07, 2021
End Date	Aug 03, 2021
Duration	88 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR131219`

Grant Description

To appraise the clinical and cost effectiveness of niraparib within its marketing authorisation as maintenance treatment of recurrent platinum-sensitive ovarian fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy.